Skip to main content
SpringerLink
Log in

DIABETIC KIDNEY DISEASE

Renoprotective effects of dulaglutide in patients with T2DM and CKD

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Potential renoprotective effects of GLP1 receptor agonists.

References

  1. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439 (2007).

    Article  CAS  Google Scholar 

  2. Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).

    Article  CAS  Google Scholar 

  3. Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018).

    Article  Google Scholar 

  4. Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280–1290 (2014).

    Article  Google Scholar 

  5. Jensen, E. P. et al. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am. J. Physiol. Renal Physiol. 308, F867–F877 (2015).

    Article  CAS  Google Scholar 

  6. Fujita, H. et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 85, 579–589 (2014).

    Article  CAS  Google Scholar 

  7. Asmar, A. et al. Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am. J. Physiol. Endocrinol. Metab. 310, E744–E753 (2016).

    Article  Google Scholar 

  8. Idorn, T. et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care 39, 206–213 (2016).

    Article  CAS  Google Scholar 

  9. Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198–207 (2012).

    Article  CAS  Google Scholar 

  10. Verma, S. et al. Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial. Circulation 137, 2179–2183 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

    Charlotte M. Sorensen & Jens J. Holst

Authors
  1. Charlotte M. Sorensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jens J. Holst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens J. Holst.

Ethics declarations

Competing interests

J.J.H. serves as a consultant for Novo Nordisk A/S and Merck Sharp & Dohme (MSD). C.M.S. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sorensen, C.M., Holst, J.J. Renoprotective effects of dulaglutide in patients with T2DM and CKD. Nat Rev Nephrol 14, 659–660 (2018). https://doi.org/10.1038/s41581-018-0055-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-018-0055-x

  • Springer Nature Limited

Search

Navigation